NOVEL BRAIN PENETRANTS; IN REDUCING THE GROWTH OF TUMOUR, TREATMENT OF GLIOBLASTOMA AND BY TARGETING BRAIN METASTASIS

Yerrajeena Ankamma*

ABSTRACT

Glioblastoma Multiforme (GBM) is a devastating brain cancer characterized by aggressive growth and limited treatment options. Despite advances in oncology, GBM patients face a dismal prognosis, with a 5-year survival rate of merely 5%.[5] The development of innovative therapies is crucial to improve outcomes for GBM patients. Recent breakthroughs have identified two promising compounds, RGN3067 and CR13626, which have demonstrated remarkable efficacy in preclinical GBM models. RGN3067, a novel tubulin destabilizer, and CR13626, a multitarget kinase inhibitor, have shown impressive tumour growth inhibition and survival benefits in orthotopic xenograft models.[4] Notably, both agents exhibit excellent oral bioavailability and brain penetration, overcoming a significant hurdle in brain cancer therapy. This review aims to provide an in-depth examination of RGN3067 and CR13626, highlighting their potential as groundbreaking therapies for GBM. By exploring their mechanisms, efficacy, and future directions, we hope to shed light on the promising horizon of GBM treatment.

Keywords: Glioblastoma, TMZ, microtubules, tubulin destabilizers, EGFR, tyrosine receptor kinase.